Intra-operative spill of favorable histology (FH) Wilms tumor cells has been thought to affect relapse-free and overall survival (OS) adversely. On National Wilms Tumor Studies (NWTS) 3-5, patients with intra-operative spill were divided into two groups: those with diffuse spillage involving the whole abdominal cavity and those with local spillage confined to the flank. Patients with diffuse spillage were treated with radiation therapy to the entire abdomen and 3-drug chemotherapy (vincristine, actinomycin-D, and doxorubicin) whereas patients with local spillage were treated with vincristine and actinomycin-D only. Based on an analysis of patients treated on NWTS-3 and -4 indicating that patients with Stage II disease and local spillage had inferior OS compared to patients with Stage II disease without local spillage [1], current Children's Oncology Group studies treat patients with local spillage with doxorubicin and flank radiation. This analysis utilized Final Stage, which was the stage and histology originally submitted by the registering institution, as the determinant of tumor stage for the analysis [1] . The Final Stage may or may not represent the actual treatment stage depending on factors such as review by the NWTSG Pathologist of a complete set of histology slides that included involved lymph nodes or formal acceptance by the registering institution of a change in stage based on the central review, among other factors.
INTRODUCTION
Intra-operative spill of favorable histology (FH) Wilms tumor cells has been thought to affect relapse-free and overall survival (OS) adversely. On National Wilms Tumor Studies (NWTS) 3-5, patients with intra-operative spill were divided into two groups: those with diffuse spillage involving the whole abdominal cavity and those with local spillage confined to the flank. Patients with diffuse spillage were treated with radiation therapy to the entire abdomen and 3-drug chemotherapy (vincristine, actinomycin-D, and doxorubicin) whereas patients with local spillage were treated with vincristine and actinomycin-D only. Based on an analysis of patients treated on NWTS-3 and -4 indicating that patients with Stage II disease and local spillage had inferior OS compared to patients with Stage II disease without local spillage [1] , current Children's Oncology Group studies treat patients with local spillage with doxorubicin and flank radiation. This analysis utilized Final Stage, which was the stage and histology originally submitted by the registering institution, as the determinant of tumor stage for the analysis [1] . The Final Stage may or may not represent the actual treatment stage depending on factors such as review by the NWTSG Pathologist of a complete set of histology slides that included involved lymph nodes or formal acceptance by the registering institution of a change in stage based on the central review, among other factors.
The present review was undertaken to determine the influence of intra-operative spillage on local relapse and survival among unirradiated patients with Stage II, FH Wilms tumor, treated with actinomycin D and vincristine only on NWTS-4, determined by retrospective determination of stage by reviewers who were blinded to outcome. Surgical checklists, operative notes, institutional pathology reports, central pathology review and flow sheets of 602 patients registered between August 1986 and September 1994 on National Wilms Tumor Study-4 as randomized, followed or switched and coded as Final Stage II, FH following central pathology review were reviewed by GJD (pediatric radiation oncologist), MHM (pediatric oncologist) or AEE (pediatric oncologist). All were reviewed by DMG (pediatric oncologist), who was blinded to the results of the other reviews. The review process included re-evaluation of the tumor stage. Stages were assigned using the NWTS-3 staging system (Table I ) [4] .
PATIENTS AND METHODS

NWTS
The stage of a tumor with thrombus present in the inferior vena cava depended upon the surgical procedure performed. When a thrombus propagating into the right atrium was removed piecemeal, the presence of residual hematogenous tumor cell spread was assumed (Stage IV). When the thrombus was transected, but removed in two pieces, one in continuity with the nephrectomy specimen and the other as a single specimen, generally accessed through the right atrium, local tumor cell contamination at the site of thrombus transection was assumed to have occurred (Stage II with spill). If the thrombus was transected, but the proximal renal vein remnant, which could contain tumor, was not resected in continuity with the proximal portion of the thrombus, the surgical margin was assumed to be positive (Stage III). If the thrombus was removed as a single specimen in continuity with the nephrectomy specimen and the renal vein remnant, and local tumor spill was not otherwise noted to have occurred, the resection was assumed to have occurred without local spill (Stage II without spill).
Statistical Methods
Relapse-free (RFS) and overall (OS) survival were estimated using the Kaplan-Meier method [5] . Hazard ratios (HRs) were estimated using the Cox model [6] and tested for statistical significance by the log-rank test [7] . Cumulative incidence curves and statistical tests comparing them for patients with and without spill were obtained using the R [8] cpmrsk package developed by Gray [9] .
RESULTS
The records of 602 patients registered between August 1986 and September 1994 on National Wilms Tumor Study-4 as randomized, followed or switched and coded as Final Stage II, FH following central pathology review were reviewed. Four hundred ninety-nine of the 602 were found after review to have Stage II, FH Wilms tumor, and are included in the current analysis. The reasons for the differences between the Final Stage in the NWTS database and the review stage are shown in Table II . The most frequent reason for exclusion was a final down-stage to I on review. Ninety-five of these patients had spill and the remaining 404 did not have spill.
The 8-year RFS percentages were 85.0% (95% confidence interval (CI): 81.1%, 88.1%) for those with no spill compared to 75.7% (65.8%, 83.2%) for those with spill (Fig. 1A) . The 8-year OS percentages were 95.6% (93.1%, 97.3%) for those with no spill compared to 90.3% (82.2%, 94.9%) for those with spill (Fig. 1B) .
Twenty-three relapses were observed among patients with spill compared to 16.3 expected (HR ¼ 1.55; 95%CI: 0.97,2.51, P ¼ 0.067). Operative bed relapse occurred in 7.4% (7/95) of those with spill compared to 2.5% (10/404) of those without spill. Relapse in the abdomen/pelvis and the operative bed comprised a larger percentage of all relapses among those with spill compared to those (Table III) . Conversely the percentage of all relapses that were confined to the lung was larger among those without spill compared to those with spill. The site of relapse within the groups of patients with and without spill by histological subtype are shown in Table IV . Local relapse was infrequent among those with epithelial or stromal predominant tumors, regardless of spill status.
The timing of local relapse differed between those with and without spill ( Fig. 2A,B) (P ¼ 0.001), but the timing of metastatic relapse (P ¼ 0.942) and the timing of death (P ¼ 0.954) did not differ statistically between those with and without spill. Among those with spill, most local relapses occurred during the first year after diagnosis whereas among those without spill, local relapses occurred throughout the first 2 years after diagnosis. Metastatic recurrences (liver, lung) occurred throughout the first 3 years after diagnosis.
Treatment of relapse differed between those with and without spill. Among those without spill, 48 (78.7%) relapsed patients were treated with doxorubicin or chest and/or abdominal irradiation, compared to 16 (72.7%) relapsed patients with spill (odds ratio (OR) ¼ 1.501; 95% CI: 0.755, 2.858) (P ¼ 0.231). Chest radiation therapy was given to 35 (57.4%) relapsed patients without spill compared to 9 (40.9%) relapsed patients with spill (OR ¼ 1.103; 95% CI: 0.449, 2.453) (P ¼ 0.841), whereas abdominal radiation therapy was given to 15 (24.6%) relapsed patients without spill compared to 7 (31.8%) relapsed patients with spill (OR ¼ 2.059; 95% CI: 0.689, 5.562) (P ¼ 0.159).
Ten deaths were observed among the patients who had tumor spill, compared to 6.1 deaths expected (HR ¼ 1.94; 95% CI: 0.92,4.09, P ¼ 0.077). Two patients with spill died more than 5 years after diagnosis, one due to tumor progression and one due to congestive heart failure. There were three cases of congestive heart failure among these patients-one among those with spill and two among those without spill. Nine patients without spill died more than 5 years after diagnosis. Five deaths were due to tumor, one was due to end stage renal disease in a patient with focal glomerulosclerosis, Type I diabetes and hypertension, and three were due to other medical conditions, two in children with multiple congenital malformations.
DISCUSSION
This analysis has demonstrated that the relapse-free survival percentage for patients with Stage II, FH Wilms tumor treated with vincristine and actinomycin D and without flank radiation therapy who experience tumor spill was 75.7% 8 years after diagnosis Pediatr Blood Cancer DOI 10.1002/pbc compared to 85.0% among those who did not experience tumor spill. The 8-year OS rates were 90.3% and 95.6% respectively. None of these differences achieved statistical significance. Treatment with radiation therapy to part of or the entire abdomen and administration of doxorubicin is currently recommended when pre-operative or intra-operative tumor spillage occurs, spreading tumor cells into the ipsilateral flank or entire peritoneal cavity [1] . Prior analyses based on patients entered on the National Wilms Tumor Study (NWTS) Group protocols suggested that the occurrence of spillage was an adverse prognostic factor for OS among patients enrolled on NWTS-1 with stages I-III renal tumors [10] , for abdominal recurrence and death among patients enrolled on NWTS-2 with stages I-III renal tumors [11] , and for abdominal recurrence and death among patients enrolled on NWTS-3 with stages I-III FH Wilms tumors [12] . Also, detailed analyses of radiation therapy parameters suggested that intraabdominal relapse was not more frequent among those patients who received lower abdominal irradiation doses, but was significantly more frequent among those with unfavorable histology (anaplasia, rhabdoid tumor of the kidney, clear cell sarcoma of the kidney) [13] .
Patients with intra-operative tumor rupture were assigned a Stage III designation on NWTS-1 and -2. Treatment of spill originally included whole abdomen irradiation in NWTS-1, but, as experience was gained in NWTS-1, when spillage was confined to the flank, irradiation was confined to the flank [14] . The staging system was modified between NWTS-2 and -3. Patients with intraoperative spillage confined to the flank were changed from Stage III (NWTS-1 and -2) to Stage II (NWTS-3) and those with peri-aortic lymph node involvement were changed from Stage II (NWTS-1 and -2) to Stage III (NWTS-3) [4, 14, 15] . Radiation therapy treatment was randomized in NWTS-3 for those with Stage II disease, including those with intra-operative tumor rupture felt by the surgeon to be confined to the ipsilateral flank, between 20 and 0 Gray (Gy). There was no evidence in NWTS-3 that the addition of either doxorubicin or radiation therapy improved the outcome for patients with Stage II, FH Wilms tumor. However no subgroup analysis within Stage II was performed to determine if those with spill independently benefited from doxorubicin and/or local radiation therapy [4] .
Analyses of outcome for stage I-IV patients treated on NWTS-4 included in a case-control study suggested that the relative risk (RR) of local recurrence in a logistic regression analysis controlled for tumor histology was 4.5 (95% confidence interval (CI): 1.4, 14.0) among Stage II patients with spill [16] . A subsequent analysis of the impact of intra-operative spillage on the risk of flank relapse and overall relapse among NWTS- an analysis adjusted for site of relapse and radiation therapy dose [1] . The current analysis demonstrated that relapse in the flank or any non-hematogenous abdominal site occurred in only 7.4% (7/95) and 9.5% (9/95) respectively of Stage II, FH Wilms tumor patients with spill compared to 2.5% (10/404) and 3.0% (12/404) of those who did not in the same order. Thus, although the risk was higher among those with spill, the absolute risk of operative bed relapse is low. Biological prognostic markers, such as loss of heterozygosity for markers of chromosomes 1p and 16q [17, 18] , were not obtained routinely on the tumor tissue of patients enrolled on NWTS-4. We thus cannot determine if these or some other marker of tumor aggressiveness might segregate with those tumors with and without spill that recurred locally or metastasized to explain the similar death rates.
Intra-operative tumor spill was a major consideration in the adoption by the International Society of Paediatric Oncology (SIOP) of the strategy of treatment of most patients with prenephrectomy chemotherapy. The randomization between immediate nephrectomy and pre-nephrectomy radiation therapy in SIOP-1 was discontinued due to the excess of intra-operative tumor ruptures among those randomized to immediate nephrectomy. Despite this difference in tumor rupture frequency, no difference in event-free or OS was reported [19] . In the United Kingdom Children's Cancer Study Group (UKW3) randomized study between immediate nephrectomy and delayed nephrectomy after pre-nephrectomy combination chemotherapy, the frequency of intra-operative tumor rupture was 0% among those who received pre-nephrectomy chemotherapy compared to 14.6% among those randomized to immediate nephrectomy. However the frequency of local relapse was higher among those who received pre-nephrectomy chemotherapy (11.0%, 10/91) than among those who underwent immediate nephrectomy (5.4%, 5/93). There were no differences in event-free or OS between the two randomized treatments [20] .
The current analyses indicate that the absolute risk of relapses in patients with Stage II, FH with or without spillage is low. The risks of deleterious late effects associated with more aggressive therapies [21] [22] [23] [24] [25] [26] [27] [28] than actinomycin D and vincristine without RT must all be considered in assessing the risk versus benefit of escalating treatment using toxic agents for children with Stage II, FH Wilms tumor, with or without tumor cell spillage.
